In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

So Regeneron donated money to a charity so it could help patients pay Medicare’s ... neither the author nor RA Capital have investments or other financial relationships with Eylea or Regeneron.

In 2019, the charity that Regeneron used to operate its patient assistance program, the Chronic Disease Fund, paid $2 million to resolve allegations that it had served as a conduit to companies ...

Regeneron's donations to independent charity foundations help elderly patients access medicines that are prescribed by their physicians." EYLEA® (aflibercept) ...

The U.S. government filed a lawsuit against Regeneron Pharmaceuticals June 24 alleging the Tarrytown, N.Y.-based drugmaker paid kickbacks to a patient assistance charity to cover Medicare copays ...

Regeneron in a statement said it would vigorously defend itself. “We do not believe there is any merit to the complaint,” the company said. Its stock price midday Wednesday was $604.62, down 3 ...

EAST GREENBUSH — Drug maker Regeneron, which employs 3,000 at its East Greenbush manufacturing plant, funneled tens of millions of dollars to a medical-assistance charity as part of a Medicare ...

Regeneron took a tough stance against the lawsuit—and picked a bone with its timing. It’s “unfortunate that the government chose to bring these baseless allegations related to our 2013 and ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said that there is no merit to the civil complaint filed by the U.S. Attorney for the District of Massachusetts.

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in ...